US · IOBT
IO Biotech, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Copenhagen 2200
- Website
- iobiotech.com
Price · as of 2024-12-31
—
Market cap 25.11M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $3.80 | ||||
| 2022 | $2.49 | ||||
| 2023 | $1.82 | ||||
| 2024 | $0.90 |
AI valuation
Our deep-learning model estimates IO Biotech, Inc.'s (IOBT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IOBT | IO Biotech, Inc. | $0.35 | 25.11M | — | — | — | — | -0.62 | 1.26 | — | -0.01 | — | 1.26 | 0.00% | — | — | -106.00% | 1021.32% | -87.44% | 0.04 | — | 3.33 | 3.14 | 0.62 | -2677.00% | — | 1434.00% | -138.96% | -4.23 | 884.12% | 0.00% | 0.00% | 0.00% | -0.01 | -0.01 | — | -9.54 |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| CUE | Cue Biopharma, Inc. | $0.28 | 22.08M | +11,310% | +57% | — | — | -1.52 | 3.54 | 6.67 | -1.26 | — | 3.54 | 100.00% | -446.86% | -437.97% | -149.03% | -1327.36% | -86.80% | 0.51 | -52.14 | 1.84 | 1.78 | 0.36 | -3514.00% | 6916.00% | -892.00% | -58.74% | -2.65 | -1164.08% | 0.00% | 0.00% | 0.00% | -1.14 | -1.30 | 5.11 | -15.88 |
| HOWL | Werewolf Therapeutics, In… | $0.60 | 29.13M | +4,114% | — | — | +21,192% | -0.76 | 0.73 | 28.28 | 0.32 | -1.37 | 0.73 | 3.77% | -3904.19% | -3740.85% | -76.33% | -517.61% | -46.74% | 0.51 | -15.81 | 7.45 | 7.31 | 1.15 | 5524.00% | -9055.00% | 6908.00% | -105.90% | -3.70 | -396.98% | 0.00% | 0.00% | 0.00% | 0.28 | 0.37 | -10.93 | -4.95 |
| INKT | MiNK Therapeutics, Inc. | $10.95 | 51.4M | — | — | — | — | -2.85 | -1.57 | — | -2.94 | — | -1.57 | 0.00% | — | — | 57.30% | 52.39% | -209.96% | -0.25 | — | 0.72 | 0.66 | -0.03 | -5719.00% | — | -3966.00% | -31.13% | -1.37 | 47.00% | 0.00% | 0.00% | 0.00% | -2.92 | -3.25 | — | -41.11 |
| KPTI | Karyopharm Therapeutics I… | $9.41 | 80.34M | +75% | -59% | — | — | -0.53 | -0.36 | 0.72 | -3.04 | -0.59 | -0.36 | 95.93% | -62.10% | -134.21% | 81.86% | 81.25% | -143.71% | -0.80 | -1.98 | 1.12 | 0.98 | -1.91 | 9054.00% | 57.00% | -4095.00% | -71.87% | -0.82 | 67.51% | 0.00% | 0.00% | 0.00% | -3.03 | -3.65 | 1.88 | -23.86 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| OTLK | Outlook Therapeutics, Inc… | $0.42 | 17.31M | — | +90,898,778% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| SPRB | Spruce Biosciences, Inc. | $54.94 | 31.88M | +1,366% | +1,346% | — | +7,284% | -20.08 | 36.96 | 216.90 | -19.54 | -498.08 | 36.96 | 100.00% | -1143.37% | -1079.94% | -100.70% | 501.62% | -71.12% | 0.10 | -182.90 | 2.90 | 2.54 | 0.68 | 403.00% | -5132.00% | 6815.00% | -5.25% | -3.67 | 499.95% | 0.00% | 0.00% | 0.00% | -18.33 | -18.39 | 209.57 | 28.03 |
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
- CEO
- Mai-Britt Zocca
- Employees
- 80
- Beta
- 0.48
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).